1. Home
  2. AUPH vs VCEL Comparison

AUPH vs VCEL Comparison

Compare AUPH & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$15.60

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo Vericel Corporation

VCEL

Vericel Corporation

HOLD

Current Price

$34.13

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AUPH
VCEL
Founded
1993
1989
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.7B
IPO Year
2014
1996

Fundamental Metrics

Financial Performance
Metric
AUPH
VCEL
Price
$15.60
$34.13
Analyst Decision
Buy
Strong Buy
Analyst Count
4
5
Target Price
$17.25
$58.50
AVG Volume (30 Days)
1.1M
666.3K
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
5075.00
60.00
EPS
2.07
0.32
Revenue
$283,055,000.00
$276,259,000.00
Revenue This Year
$16.53
$19.10
Revenue Next Year
$16.24
$17.95
P/E Ratio
$7.48
$101.75
Revenue Growth
20.38
16.45
52 Week Low
$6.83
$28.95
52 Week High
$16.54
$45.97

Technical Indicators

Market Signals
Indicator
AUPH
VCEL
Relative Strength Index (RSI) 63.33 53.23
Support Level $14.56 $30.41
Resistance Level $16.28 $34.34
Average True Range (ATR) 0.52 1.76
MACD 0.15 0.26
Stochastic Oscillator 99.72 77.58

Price Performance

Historical Comparison
AUPH
VCEL

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

About VCEL Vericel Corporation

Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Share on Social Networks: